HLX03 (adalimumab biosimilar)
GPTKB entity
Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
biosimilar |
| gptkbp:approvalYear |
2020
|
| gptkbp:ATCCode |
L04AB04
|
| gptkbp:biosimilar |
gptkb:adalimumab
|
| gptkbp:developer |
gptkb:Shanghai_Henlius_Biotech
|
| https://www.w3.org/2000/01/rdf-schema#label |
HLX03 (adalimumab biosimilar)
|
| gptkbp:indication |
rheumatoid arthritis
ankylosing spondylitis plaque psoriasis |
| gptkbp:macromoleculeType |
gptkb:IgG1
|
| gptkbp:mechanismOfAction |
TNF inhibitor
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:status |
approved in China
|
| gptkbp:target |
gptkb:tumor_necrosis_factor_alpha
|
| gptkbp:bfsParent |
gptkb:Shanghai_Henlius_Biotech
|
| gptkbp:bfsLayer |
7
|